A type II segmental vitiligo developed under infliximab treatment for ulcerative colitis

Tae Hyung Ryu; Dong Won Lee; Jae Eun Choi; Hyo Hyun Ahn; Young Chul Kye; Soo Hong Seo

doi:10.5021/ad.2017.29.6.826

A type II segmental vitiligo developed under infliximab treatment for ulcerative colitis

Tae Hyung Ryu, Dong Won Lee, Jae Eun Choi, Hyo Hyun Ahn, Young Chul Kye, Soo Hong Seo

Department of Dermatology

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	826-827
Number of pages	2
Journal	Annals of Dermatology
Volume	29
Issue number	6
DOIs	https://doi.org/10.5021/ad.2017.29.6.826
Publication status	Published - 2017 Dec

ASJC Scopus subject areas

Dermatology

Access to Document

10.5021/ad.2017.29.6.826

Cite this

@article{e1c2610b84704e0c8c1fddf94abad618,

title = "A type II segmental vitiligo developed under infliximab treatment for ulcerative colitis",

author = "Ryu, {Tae Hyung} and Lee, {Dong Won} and Choi, {Jae Eun} and Ahn, {Hyo Hyun} and Kye, {Young Chul} and Seo, {Soo Hong}",

year = "2017",

month = dec,

doi = "10.5021/ad.2017.29.6.826",

language = "English",

volume = "29",

pages = "826--827",

journal = "Annals of Dermatology",

issn = "1013-9087",

publisher = "Korean Dermatological Association",

number = "6",

}

TY - JOUR

T1 - A type II segmental vitiligo developed under infliximab treatment for ulcerative colitis

AU - Ryu, Tae Hyung

AU - Lee, Dong Won

AU - Choi, Jae Eun

AU - Ahn, Hyo Hyun

AU - Kye, Young Chul

AU - Seo, Soo Hong

PY - 2017/12

Y1 - 2017/12

UR - http://www.scopus.com/inward/record.url?scp=85035342466&partnerID=8YFLogxK

U2 - 10.5021/ad.2017.29.6.826

DO - 10.5021/ad.2017.29.6.826

M3 - Letter

AN - SCOPUS:85035342466

VL - 29

SP - 826

EP - 827

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 6

ER -

A type II segmental vitiligo developed under infliximab treatment for ulcerative colitis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this